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Abstract
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency state
in humans. The clinical phenotype is variable and includes asymptomatic individuals, episodic hemolysis induced by
oxidative stress, and chronic hemolysis. G6PD deficiency is common in malaria-endemic regions, an observation
hypothesized to be due to balancing selection at the G6PD locus driven by malaria. G6PD deficiency increases risk
of severe malarial anemia, a key determinant of invasive bacterial disease in malaria-endemic settings. The
pneumococcus is a leading cause of invasive bacterial infection and death in African children. The effect of G6PD
deficiency on risk of pneumococcal disease is undefined. We hypothesized that G6PD deficiency increases
pneumococcal disease risk and that this effect is dependent upon malaria.
Methods: We performed a genetic case-control study of pneumococcal bacteremia in Kenyan children stratified
across a period of falling malaria transmission between 1998 and 2010.
Results: Four hundred twenty-nine Kenyan children with pneumococcal bacteremia and 2677 control children
were included in the study. Among control children, G6PD deficiency, secondary to the rs1050828 G>A mutation,
was common, with 11.2% (n = 301 of 2677) being hemi- or homozygotes and 33.3% (n = 442 of 1329) of girls being
heterozygotes. We found that G6PD deficiency increased the risk of pneumococcal bacteremia, but only during a
period of high malaria transmission (P = 0.014; OR 2.33, 95% CI 1.19–4.57). We estimate that the population
attributable fraction of G6PD deficiency on risk of pneumococcal bacteremia in areas under high malaria
transmission is 0.129.
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Conclusions: Our data demonstrate that G6PD deficiency increases risk of pneumococcal bacteremia in a manner
dependent on malaria. At the population level, the impact of G6PD deficiency on invasive pneumococcal disease
risk in malaria-endemic regions is substantial. Our study highlights the infection-associated morbidity and mortality
conferred by G6PD deficiency in malaria-endemic settings and adds to our understanding of the potential indirect
health benefits of improved malaria control.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) catalyzes
the oxidation of glucose-6-phosphate, producing 6-
phosphogluconolactone and dihydronicotinamide aden-
ine dinucleotide phosphate (NADPH) [1]. NADPH is a
reducing agent that is central to the mechanism by
which cells mitigate oxidative stress. This is especially
important for erythrocytes, which, not possessing mito-
chondria, lack alternative metabolic pathways for
NADPH synthesis. In humans, G6PD is encoded by an
X-linked locus: G6PD.
G6PD is highly polymorphic. Deleterious G6PD poly-
morphisms result in the most common human enzyme
deficiency: G6PD deficiency [1]. The X-linked inherit-
ance of such polymorphisms means that G6PD defi-
ciency is limited to hemizygous males and homozygous
females, while heterozygous females display an inter-
mediate phenotype. G6PD deficiency can cause a wide
spectrum of clinical disease, the severity of which is
dependent on the level of residual enzyme activity. In in-
dividuals with symptomatic G6PD deficiency, disease
commonly manifests as episodic hemolysis induced by
oxidative stress (e.g., drugs, infection). More severe de-
fects cause chronic hemolysis, characterized by chronic
transfusion-dependent anemia, splenomegaly, and the
formation of gallstones [2]. An immunodeficiency char-
acterized by granulocyte dysfunction and a clinical
phenotype similar to chronic granulomatous disease has
also been described in severe enzymatic deficiency [3].
The major genetic determinant of G6PD deficiency in
coastal Kenyan populations is the rs1050828 G>A muta-
tion [4], which gives rise to a form of G6PD deficiency
that is commonly referred to as the G6PD A− variant.
G6PD A− is a WHO class 3 G6PD deficiency variant [5],
predicted to result in only mild-to-moderate enzymatic
deficiency (10–60% of normal). This genetic variant of
G6PD deficiency is estimated to account for 85% of
phenotypic variation in G6PD enzymatic activity in
coastal Kenyan populations [4]. Among female heterozy-
gous for the G6PD A− variant in coastal Kenya, G6PD
enzymatic activity is determined by variation at a second
SNP at the G6PD locus, rs1050829 [4]. rs1050829 is a
WHO class 4 G6PD deficiency variant, predicted to
result in a clinically asymptomatic decrease in G6PD en-
zymatic activity (< 40% reduction from wild type). Vari-
ation at rs1050829 does not affect residual enzymatic
activity in individuals with G6PD deficiency secondary
to the G6PD A− variant in African populations, as the
G6PD A− variant is always inherited on a rs1050829:C
background [4].
The geographic distribution of G6PD deficiency is
strongly correlated with malaria transmission. This has
led to the hypothesis that malaria has driven selection of
G6PD deficiency variants in human populations. That
hypothesis is supported by evidence of recent selection
pressure at G6PD [6] and by studies defining the effect
of G6PD variation on malaria risk [7, 8]. The exact na-
ture of the selection pressure imposed by malaria at
G6PD remains controversial. We have previously dem-
onstrated that, in Kenyan children, G6PD status is not
associated with uncomplicated malaria, but that G6PD
deficiency secondary to the G6PD A− variant increases
the risk of severe malarial anemia (SMA), whereas het-
erozygous females are protected against severe malaria
[7]. In the same population, we found no evidence for an
independent effect of C allele carriage at rs1050829 on
risk of uncomplicated or severe malaria [7]. Further-
more, through a multi-population analysis of the effect
of variation at G6PD on malaria risk, we have recently
demonstrated that G6PD deficiency is associated with
opposing additive effects on cerebral malaria and SMA
[8]. In that analysis, G6PD deficiency was associated
with increased susceptibility to SMA but a lower risk of
cerebral malaria [8]. More recently, however, it has been
suggested that this observation may represent an artifact
of collider bias [9]: by excluding children with severe
anemia from the case definition of cerebral malaria, the
apparent protective association may be driven by an ab-
sence of severe anemia and not cerebral malaria per se.
Notwithstanding on-going uncertainty regarding the
exact nature of the balancing selection at the G6PD
locus driven by malaria, there is a clear and reproducible
association between G6PD deficiency and risk of SMA.
The effect of genetic variation at G6PD on infectious
diseases other than malaria has not been widely studied.
Specifically, the role for genetic variation at the G6PD
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locus as a determinant of invasive bacterial disease is un-
defined. Streptococcus pneumoniae is consistently among
the most frequently isolated pathogens causing
bacteremia in African children [10] and is a leading
cause of mortality in children < 5 years [11]. Genetic
variation at G6PD modifies risk of SMA. SMA is a major
risk factor for community-acquired bacteremia in Afri-
can children [12, 13], and the malaria-protective effects
of HbAS carriage reduce the risk of some of the clinical
syndromes that are associated with invasive pneumococ-
cal diseases such as severe pneumonia and meningitis
[14]. Moreover, severe anemia in African children, irre-
spective of its etiology, is associated with increased risk
of community-acquired bacteremia [15]. We thus hy-
pothesized that G6PD deficiency increases the risk of
pneumococcal bacteremia in African children and that
this effect is dependent on intense malaria transmission
resulting in severe anemia among G6PD-deficient chil-
dren. To test this hypothesis, we performed a genetic
case-control analysis of the effect of G6PD deficiency on
the risk of pneumococcal bacteremia in Kenyan children,
across a period of falling malaria transmission.
Methods
Study population, genotyping, and quality control
Kenyan children under the age of 13 years, presenting to
Kilifi County Hospital, Kenya, between 1 August 1998
and 30 October 2010, with community-acquired
bacteremia were recruited to the study. Routine vaccin-
ation against S. pneumoniae was not available during the
study period and was not introduced until January 2011.
During the study period, a blood sample for bacterial
culture was obtained from every child admitted to
hospital, with the exception of elective surgical admis-
sions and children admitted with trauma. Bacterial
culture of blood was performed with a BACTEC 9050
instrument (Becton Dickinson, USA), and pneumococ-
cal isolates identified by optochin susceptibility. Chil-
dren with a mid-upper arm circumference < 11.5 cm
(< 11 cm in children < 6 months of age) were consid-
ered to have severe malnutrition. HIV infection status
was determined with two rapid antibody tests and
with PCR for proviral DNA for children < 18 months.
Malaria parasitemia was assessed using thick and thin
Giemsa-stained blood films. Among children with all-
cause bacteremia (n = 1816), 506 cases of pneumococ-
cal bacteremia were recruited to the study. Healthy
community controls (n = 3091) were recruited as part
of a birth cohort study at 3–12 months of age from
within the same population as cases between 1 May
2006 and 30 April 2008. All children have been sub-
ject to longitudinal follow-up.
Genome-wide genotyping was performed in all study
samples as part of the Wellcome Trust Case Control
Consortium 2 genome-wide association study (GWAS)
of all-cause bacteremia [16]. Following genomic DNA
extraction and quality control, DNA was whole-genome
genotyped on Affymetrix SNP Chip 6.0 arrays. SNPs
passing the following quality control (QC) metrics (MAF
> 1%, genotype probability (info) > 0.975, plate effect P >
1 × 10−6, Hardy-Weinberg equilibrium P < 1 × 10−10, and
SNP missingness > 2%) were included in the analysis.
Following SNP QC, genotypes at 787,861 autosomal
SNPs were taken forward for computation of principal
components (EIGENSTRAT [17]) following linkage dis-
equilibrium pruning, relatedness estimates (identity by
descent, PLINK [18]) and heterozygosity (PLINK). Sam-
ples were then excluded from the association analysis as
follows: relatedness (identity by descent > 0.4), popula-
tion outliers, extreme heterozygosity, or low genotyping
call rate [16].
Genotypes at rs1050828 were directly determined on
the genotyping array. Genotyping quality at rs1050828
was good, passing SNP QC thresholds (as above) and
with good cluster separation (visualized in Evoker). Ge-
notypes at rs1050829 and the 4 malaria risk loci (ABO,
rs8176719; Dantu blood group, rs192804806; sickle
hemoglobin [HbS], rs334; ATP2B4, rs4951377) were not
directly determined and were imputed with SHAPEIT
[19] and IMPUTE2 [20], using 1000G phase 3 as a refer-
ence panel. Following quality control, 429 cases of S.
pneumoniae bacteremia and 2677 healthy control sam-
ples were included in the association analysis.
Statistical analysis
Association analysis at G6PD
We used logistic regression to test for association be-
tween pneumococcal bacteremia and G6PD A− vari-
ant (rs1050828) genotype under additive (rs1050828
genotypes coded to reflect a monotonic change in
G6PD biochemical activity), G6PD deficiency (G6PD
deficiency c.f. normal G6PD activity), and G6PD het-
erozygous (rs1050828:T heterozygous girls c.f. normal
G6PD activity) models. In a separate model, we used
logistic regression to test for association between
pneumococcal bacteremia and rs1050829 genotype
among G6PD A− heterozygous females under an
additive model. The first four principal components
of genome-wide genotyping data were included in each
model to account for population sub-structure. In addition,
sex was included as a covariate in each model. Statistical
analysis was performed in R.
Multinomial logistic regression
As control samples were recruited as a birth cohort to-
wards the end of the study, we used multinomial logistic
regression to estimate the effect of the G6PD variation
on pneumococcal bacteremia risk in each of the three
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phases of malaria transmission (pre-decline, pre-2000;
decline, 2000–2006; post-decline, post-2006). We used
control status as the baseline stratum and cases of
pneumococcal bacteremia during each of the specified
time periods as strata. We tested for association
under additive, G6PD deficiency, and G6PD heterozy-
gous models (as defined above) at rs1050828, and the
effect of rs1050829 genotype in rs1050828 heterozy-
gous girls under an additive model. In each case, the
first four principal components and sex were included
as covariates in the model. To address the possibility
of confounding secondary to other known malaria
risk loci, we also included genotypes at each locus in
the model, with genotypes coded to reflect the model
of association observed in malaria (ABO, recessive;
Dantu blood group, additive; HbS, heterozygote and
recessive; ATP2B4, recessive).
To identify a subset of control samples well-
matched to cases with respect to sex and ethnicity (as
modeled by the first 4 principal components of
genome-wide genotyping data), we used nearest
neighbor matching as implemented in MatchIt [21].
The proportions of case children with HIV infection
and malnutrition were compared between time pe-
riods using χ2 tests. Under the assumption that G6PD
deficiency and HIV infection or malnutrition are in-
dependent, we performed case-only interaction ana-
lysis with logistic regression adjusted for sex and
population structure. Statistical analysis was per-
formed in R.
Bayesian comparison of models of association
We compared models of association at rs1050828 with
pneumococcal bacteremia across three time periods, as
estimated by multinomial logistic regression, using a
Bayesian approach. We considered three models of effect
across the specified time periods defined by the prior
distributions on the effect size:
“Null”: effect size = 0, i.e., no association in any time
period.
“Same”: effect size ~ N (0,a2) and fixed between time
periods (ρ = 1).
“Pre-decline alone”: effect size ~ N (0,a2) in the pre-
decline period only (with no effect in the other time
periods).
For heterozygous and G6PD deficiency models, a =
0.5, and for additive models, a = 0.2. For each model,
we calculated approximate Bayes factors [22] and
posterior probabilities, assuming each model to be
equally likely a priori. Statistical analysis was per-
formed in R.
Population attributable fraction
Population attributable fractions were calculated as
follows:
PAF ¼ P OR−1ð Þ
P OR−1ð Þ þ 1
where PAF = population attributable fraction, OR =
odds ratio, and P = population frequency of risk
genotype(s).
Results
Study population
Following quality control, 429 Kenyan children with
pneumococcal bacteremia and 2677 control participants
were included in our genetic association analysis. The
first four principal components of genome-wide geno-
typing data capture self-reported ethnicity and confirm
that the population structure of the control samples is
representative of the cases (Fig. 1). The mean age among
case samples was 1.9 years (range 0–13 years), and 38.7%
were female. Among cases, at admission, 25.9% had mal-
nutrition, 12.2% had malaria parasitemia, and 20.8%
were HIV-infected (Table 1). Inpatient mortality was
24%. The use of a birth cohort as a healthy control
population risks loss of study power through misclassifi-
cation bias: the inclusion of children as healthy controls
who have subsequently experienced an episode of
pneumococcal bacteremia. Follow-up of the control chil-
dren demonstrates that the effect of misclassification
bias in our study is negligible. Following longitudinal
follow-up to an average age of 5.1 years, there were 8
cases of all-cause bacteremia and 24 deaths among the
control children included in the study.
Genetic variation causing G6PD deficiency
Among control samples, rs1050828 had a minor allele
frequency (MAF) of 0.196. G6PD deficiency, defined by
homozygous rs1050828:AA or hemizygous rs1050828:A
genotypes, was common (n = 301 of 2677; 11.2%). 3.2%
of girls (n = 42 of 1329) and 19.2% of boys (n = 259 of
1348) had homozygous and hemizygous A allele carriage
at rs1050828, respectively, resulting in G6PD deficiency.
One third (33.3%, n = 442 of 1329) of girls were hetero-
zygous for rs1050828:A carriage. rs1050829 was well-
imputed and common in this dataset (imputation info
metric = 0.981; MAF = 0.396). In the study population,
27.9% (n = 1175 of 4213) were homozygous or hemizy-
gous for the minor rs1050829:C allele. Among female
rs1050828:T heterozygotes, 74.9% (n = 490 of 654) were
rs1050829:TC heterozygotes and 25.1% (n = 164 of 654)
were rs1050829:CC homozygotes. The 4 malaria risk loci
previously described in this population [23] were com-
mon and well-imputed among the study samples
Gilchrist et al. BMC Medicine          (2020) 18:148 Page 4 of 10
Fig. 1 Population structure of study samples. Plots of the first four principal components of genome-wide genotyping data. Individuals are color-
coded according to self-reported ethnicity (a) and case-control status (b)
Table 1 Study sample demographics, case comorbidities, and inpatient mortality
Cases Controls
Median age in months (range) 23 (0–157) *
Females, n (%) 166 (38.7) 1329 (49.6)
Reported ethnicity Giriama, n (%) 167 (38.9) 1226 (45.8)
Chonyi, n (%) 78 (18.2) 993 (37.1)
Kauma, n (%) 22 (5.1) 318 (11.9)
Comorbidities HIV-infected, n (%)** 25 (20.8) NA
Malnutrition, n (%) 108 (25.9) NA
Malaria, n (%) 44 (12.2) NA
Mortality, n (%) 101 (24.0) NA
NA not applicable
*Birth cohort
**HIV-status ascertained in subset of cases
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(rs8176719, imputation info metric = 0.994, MAF =
0.259; rs334, imputation info metric = 0.932, MAF =
0.097; rs192804806, imputation info metric = 0.987,
MAF = 0.092; rs4951377, imputation info metric = 0.995,
MAF = 0.658).
G6PD status and risk of pneumococcal bacteremia
To investigate whether G6PD status is a determinant of
pneumococcal bacteremia risk, we tested for association
between the rs1050828 locus and pneumococcal
bacteremia. Genotype at rs1050828 (Padditive = 0.261;
OR = 1.08, 95% CI 0.94–1.25), G6PD deficiency (P =
0.080; OR = 1.30, 95% CI 0.96–1.74), and heterozygous
carriage of the rs1050828:A allele (P = 0.326; OR = 0.83,
95% CI 0.56–1.19) were not associated with risk of
pneumococcal bacteremia. In addition, among female
rs1050829 G>A heterozygotes, rs1050829 carriage did
not modify risk of pneumococcal bacteremia (Padditive =
0.452; OR = 0.75, 95% CI 0.36–1.58).
G6PD deficiency increases risk of pneumococcal
bacteremia during an era of high malaria transmission
Over the course of case recruitment, between 1998 and
2008, there was a marked change in malaria transmis-
sion intensity in Kilifi [24]. Historically, malaria has been
a major risk factor for community-acquired bacteremia
in this population [13]. Declining malaria transmission
may therefore confound any association between
bacteremia and G6PD deficiency. To investigate this, we
estimated the effect of G6PD status on pneumococcal
bacteremia risk as malaria transmission declined over
the period of the study. Dividing the study period into
pre-decline (pre-2000), decline (2000–2006), and post-
decline (post-2006) periods, we fitted multinomial re-
gression models of pneumococcal bacteremia risk sec-
ondary to G6PD status, considering each time period as
a stratum (Fig. 2). Under an additive model, the data
provide support for a model in which decreasing G6PD
activity (estimated by rs1050828 genotype) only in-
creased the risk of pneumococcal bacteremia during the
pre-decline period (ORPre-decline = 1.41, 95% CI 1.01–
1.97, PPre-decline = 0.044). However, the data more
strongly support a model in which G6PD deficiency, de-
fined by homozygous rs1050828:AA or hemizygous
rs1050828:A genotypes, increased risk of pneumococcal
bacteremia, again in the pre-decline period alone
(ORPre-decline = 2.33, 95% CI 1.19–4.57, PPre-decline =
0.014). We found no evidence for a significant effect of
heterozygous carriage of rs1050828:A on pneumococcal
bacteremia risk in any time period. We saw no evidence
for a significant effect of rs1050829:C carriage on
pneumococcal bacteremia risk in any time period.
To ensure that our model adequately controls for dif-
ferences in sex and population structure, we used
propensity score matching to identify a subset of control
samples (n = 429) matched to cases for sex and popula-
tion structure. In keeping with our primary analysis,
there is again evidence for increased risk of pneumococ-
cal disease among children with G6PD deficiency
(ORPre-decline = 2.54, 95% CI 1.23–5.25, PPre-decline =
0.012). There is no evidence for effect of G6PD defi-
ciency on pneumococcal disease risk in the decline and
post-decline study periods (PDecline = 0.271, PPost-decline =
0.442).
G6PD deficiency increases risk of pneumococcal
bacteremia independent of other risk factors for invasive
infection
Both HIV infection and malnutrition are established risk
factors for pneumococcal bacteremia in this population
[26]. We therefore sought to understand whether
changes in the epidemiology of malnutrition or HIV in-
fection during the study could confound our findings.
We compared the proportions of cases with HIV co-
infection and malnutrition presenting during the pre-
decline period and during later years. There was evi-
dence for a temporal change in the proportion of cases
with malnutrition (pre-2000, 12 of 47 children, 25.5%;
post-2000, 86 of 370 children, 23.2%; P = 5.13 × 10−4),
but not with HIV infection (pre-2000, 11 of 44 children,
25%; post-2000, 14 of 86 children, 16.3%; P = 0.233).
There was no evidence for interaction between G6PD
deficiency and malnutrition or HIV among cases of
pneumococcal bacteremia in the study considered as a
whole (PMalnutrition = 0.92; PHIV = 0.77) or during the pre-
decline period alone (PMalnutrition = 0.85; PHIV = 0.48).
Genome-wide association studies have identified 4
genetic determinants of severe malaria risk in this popu-
lation (ABO blood group, HbS, Dantu blood group, and
ATP2B4) [23]. We investigated whether the observed as-
sociation between G6PD deficiency and the risk of
pneumococcal bacteremia was independent of genetic
variation at these loci. Including genetic variation at
these loci did not significantly alter the effect estimate of
G6PD deficiency on pneumococcal bacteremia risk in
the study considered as a whole (OR = 1.28, 95% CI
0.95–1.73, P = 0.101) or during the pre-decline period
alone (OR = 2.32, 95% CI 1.18–4.56, P = 0.015).
The population attributable fraction of pneumococcal
bacteremia
To better understand the impact of G6PD deficiency on
pneumococcal disease risk, we calculated the population
attributable fraction prior to the observed decline in
malaria transmission at the study site. In the pre-decline
period, the pneumococcal bacteremia population attrib-
utable fraction for G6PD deficiency was 0.129. For com-
parison, assuming an OR for pneumococcal bacteremia
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Fig. 2 (See legend on next page.)
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among children with sickle cell disease (HbSS) of 33.0
[27] and a mean HbSS frequency among children < 14
years in this population of 0.003 [27], the population at-
tributable fraction of pneumococcal bacteremia for
HbSS would be 0.088.
Discussion
In Kenyan children, G6PD deficiency increases risk of
pneumococcal bacteremia. This effect is only observed
prior to a decline in malaria transmission at the study
site. Heterozygous carriage of the rs1050828:A allele
does not significantly affect risk of pneumococcal
bacteremia in this population. These data demonstrate
that G6PD deficiency increases risk of pneumococcal
bacteremia in Kenyan children and that this effect is
dependent on malaria.
Malaria is a well-established risk factor for community-
acquired bacteremia [13]. Children with G6PD deficiency
secondary to the G6PD A− variant have increased risk of
SMA in this population [7]. Epidemiological [28] and im-
munological [29] data have defined a role for SMA in sus-
ceptibility to invasive bacterial disease, including
pneumococcal bacteremia. In keeping with this, we ob-
served a malaria-dependent increase in risk of pneumo-
coccal bacteremia among children with G6PD deficiency
secondary to the G6PD A− variant. By contrast, carriage
of the rs1050829:C allele, a WHO class 4 deficiency vari-
ant, was not associated with increased risk of SMA in
Kenyan children [7] and was not associated with increased
risk of pneumococcal bacteremia in this study. This effect
may therefore reflect an increased risk of SMA among
G6PD-deficient children. It is important to note, however,
that the increased risk of malaria-induced hemolysis con-
ferred by G6PD deficiency will result in anemia and im-
munological deficits that will persist beyond the index
malaria infection. Indeed, in this population, recent mal-
aria infection is a stronger predictor of nontyphoidal Sal-
monella bacteremia than concurrent malaria [30].
We did not see any protective effect of heterozygosity
at G6PD on pneumococcal bacteremia risk. Bacteremia
complicating cerebral malaria is uncommon. If the
malaria-protective effects of G6PD deficiency heterozy-
gosity are restricted to cerebral malaria, these effects
would not be predicted to modify invasive bacterial
disease risk, consistent with our observations. That we
do not observe a protective effect of G6PD deficiency
heterozygosity on pneumococcal disease risk may sug-
gest that G6PD deficiency alleles do indeed confer
specific protection against cerebral malaria, but may
equally represent a lack of study power to detect such
an effect. Future studies are needed to clarify protect-
ive effects of G6PD deficiency heterozygosity on mal-
aria and bacteremia risk.
Malaria control interventions have effects on mortality
among African children in excess of those attributable to
the observed reduction in severe malaria syndromes [31,
32]. In this study, G6PD deficiency was estimated to ac-
count for 13% of cases of pneumococcal bacteremia, but
only during a period of high malaria transmission. This
highlights the significant risk of morbidity and mortality
secondary to invasive pneumococcal disease conferred
by G6PD deficiency in malaria-endemic settings. These
data also highlight that health outcomes for children
with G6PD deficiency will be improved by better malaria
control interventions and that these benefits will be both
directly and indirectly attributable to improved malaria
control.
Conclusions
Our data define a role for G6PD deficiency in susceptibil-
ity to pneumococcal bacteremia in Kenyan children. We
propose a model in which G6PD deficiency increases risk
of malaria-induced anemia in Kenyan children, thereby
increasing risk of invasive pneumococcal disease. Our
data highlight the importance of G6PD deficiency as
a determinant of susceptibility to infection and
further highlights the potential indirect benefits of
improved malaria control in malaria-endemic
populations.
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